PHARMACODYNAMICS OF BIOLOGICAL RESPONSE INVIVO AFTER SINGLE AND MULTIPLE DOSES OF INTERFERON-BETA

被引:63
作者
WITT, PL
STORER, BE
BRYAN, GT
BROWN, RR
FLASHNER, M
LAROCCA, AT
COLBY, CB
BORDEN, EC
机构
[1] UNIV WISCONSIN,CTR CLIN CANC,MADISON,WI 53706
[2] BERLEX LABS INC,ALAMEDA,CA
来源
JOURNAL OF IMMUNOTHERAPY | 1993年 / 13卷 / 03期
关键词
BETA-2-MICROGLOBULIN; NEOPTERIN; TRYPTOPHAN; 2'; 5'-OLIGOADENYLATE SYNTHETASE; INTERFERON;
D O I
10.1097/00002371-199304000-00006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Interferons (IFNs) induce gene regulation in vivo that may be used to identify effective doses, schedules, and potential correlates of therapeutic response. To critically examine minimum effective dose, duration of response, and cumulative effects of repetitive doses, a range of subcutaneous doses of IFNbeta(ser) was studied in 32 healthy human volunteers. IFN-induced products of gene regulation assessed were beta2-microglobulin, neopterin, and tryptophan in serum and 2',5'-oligoadenylate (2-5A) synthetase activity in peripheral blood mononuclear cells. Eight subjects per group received 0.09, 0.9, 9, or 45 MU of IFNbeta. Responses were measured at 24, 48, and 72 h after single and multiple doses. The lowest biologically effective dose was 0.9 MU; significant (p < 0.02) increases were observed at 24 h in beta2-microglobulin and cellular 2-5A synthetase activity. At the two higher doses, 9 and 45 MU, changes were observed at 24 h in all products (p < 0.01). A dose response (p < 0.01) over the range of 0.09-45 MU was observed for all these serum and intracellular gene products. Changes in neopterin, beta2-microglobulin, and cellular 2-5A synthetase correlated significantly with each other. The response to a single dose of IFNbeta was as great in magnitude as the response to multiple doses, suggesting an alternate-day schedule would maintain biological response.
引用
收藏
页码:191 / 200
页数:10
相关论文
共 45 条
[1]   SUCCESSFUL TREATMENT OF METASTATIC RENAL-CELL CARCINOMA WITH A BIOLOGICALLY-ACTIVE DOSE OF RECOMBINANT INTERFERON-GAMMA [J].
AULITZKY, W ;
GASTL, G ;
AULITZKY, WE ;
HEROLD, M ;
KEMMLER, J ;
MULL, B ;
FRICK, J ;
HUBER, C .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (12) :1875-1884
[2]   INTERFERON-GAMMA FOR THE TREATMENT OF METASTATIC RENAL-CANCER - DOSE-DEPENDENT STIMULATION AND DOWN-REGULATION OF BETA-2 MICROGLOBULIN AND NEOPTERIN RESPONSES [J].
AULITZKY, W ;
GASTL, G ;
AULITZKY, WE ;
NACHBAUR, K ;
LANSKE, B ;
KEMMLER, G ;
FLENER, R ;
FRICK, J ;
HUBER, C .
IMMUNOBIOLOGY, 1987, 176 (1-2) :85-95
[3]  
BORDEN EC, 1990, CANCER, V65, P800, DOI 10.1002/1097-0142(19900201)65:3+<800::AID-CNCR2820651328>3.0.CO
[4]  
2-Y
[5]   CLINICAL AND BIOLOGICAL EFFECTS OF RECOMBINANT INTERFERON-BETA ADMINISTERED INTRAVENOUSLY DAILY IN PHASE-I TRIAL [J].
BORDEN, EC ;
HAWKINS, MJ ;
SIELAFF, KM ;
STORER, BM ;
SCHIESEL, JD ;
SMALLEY, RV .
JOURNAL OF INTERFERON RESEARCH, 1988, 8 (03) :357-366
[6]   BIOLOGICAL AND CLINICAL EFFECTS OF INTERFERON-BETA-SER AT 2 DOSES [J].
BORDEN, EC ;
RINEHART, JJ ;
STORER, BE ;
TRUMP, DL ;
PAULNOCK, DM ;
TEITELBAUM, AP .
JOURNAL OF INTERFERON RESEARCH, 1990, 10 (06) :559-570
[7]  
BROWN RR, 1989, CANCER RES, V49, P4941
[8]   ENHANCEMENT OF INDOLEAMINE 2,3-DIOXYGENASE ACTIVITY IN CANCER-PATIENTS RECEIVING INTERFERON-BETA-SER [J].
CARLIN, JM ;
BORDEN, EC ;
BYRNE, GI .
JOURNAL OF INTERFERON RESEARCH, 1989, 9 (02) :167-173
[9]  
CINEL A, 1991, Clinical and Experimental Obstetrics and Gynecology, V18, P91
[10]  
CLAUSS IM, 1990, BLOOD, V76, P2337